Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis (Go-Thermal)
A Pilot Study to Evaluate the Utility of Thermography in Assessing Response to Golimumab Treatment in Psoriatic Arthritis
Sponsor: Imperial College Healthcare NHS Trust
Terminated
The study was stopped due to resourcing issues.
Listed as NCT02841176, this NA trial focuses on Psoriatic Arthritis and remains terminated or withdrawn. Sponsored by Imperial College Healthcare NHS Trust, it has been updated 9 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)Psoriatic Arthritis is a joint problem (arthritis) that often occurs with a skin condition called psoriasis. Psoriasis is a common skin problem that causes red patches on the body, and it is an on-going (chronic) inflammatory condition. About 1 in 20 people with psoriasis will develop arthritis with the skin condition. In most cases, psoriasis comes before the arthritis. The cause of Psoriatic Arthritis is not known.
Psoriatic Arthritis can be treated using different types of drugs to reduce pain and swelling of the joints. New medicines that block an inflammatory protein called tumor necrosis factor (TNF) are being widely used for progressive Psoriatic Arthritis, as is the case of the drug Golimumab.
Thermography is the use of images to study heat distribution in different parts of the body, and allows one to see variations in temperature, for example in detecting joint inflammation.
This is a pilot study to evaluate whether thermography is able to reliably detect joint inflammation in Psoriatic Arthritis, and whether it is able to detect improvement or worsening in inflammation during medical treatment with Golimumab. This involves assessing disease activity using some questionnaires, examining of patient joints, performing blood tests, ultrasound and thermography.
Psoriatic Arthritis is a joint problem (arthritis) that often occurs with a skin condition called psoriasis. Psoriasis is a common skin problem that causes red patches on the body, and it is an on-going (chronic) inflammatory condition. About 1 in 20 people with psoriasis will develop arthritis with the skin condition. In most cases, psoriasis comes before the arthritis. The cause of Psoriatic Arthritis is not known.
Psoriatic Arthritis can be treated using different types of drugs to reduce pain and swelling of the joints. New medicines that block an inflammatory protein called tumor necrosis factor (TNF) are being widely used for progressive Psoriatic Arthritis, as is the case of the drug Golimumab.
Thermography is the use of images to study heat distribution in different parts of the body, and allows one to see variations in temperature, for example in detecting joint inflammation.
This is a pilot study to evaluate whether thermography is able to reliably detect joint inflammation in Psoriatic Arthritis, and whether it is able to detect improvement or worsening in inflammation during medical treatment with Golimumab. This involves assessing disease activity using some questionnaires, examining of patient joints, performing blood tests, ultrasound and thermography.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Terminated NA
-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jun 2022 — Jul 2024 [monthly]
Terminated NA
-
Jan 2021 — Jun 2022 [monthly]
Terminated NA
▶ Show 4 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Terminated NA
Status: Unknown Status → Terminated
-
Nov 2018 — Apr 2019 [monthly]
Unknown Status NA
-
Jun 2018 — Nov 2018 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Imperial College Healthcare NHS Trust
- Imperial College London
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .